GLP-1 RA Microdosing: A Scalable Solution for Modern NPs
GLP-1s aren’t just for weight loss or diabetes. They’re a longevity lever and most NPs have no idea how to use them correctly.
GLP-1 receptor agonists are the most talked-about drug class in medicine. But the conversation in most clinical settings is still stuck at two extremes: prescribe semaglutide at full titration for weight loss, or prescribe it for Type 2 diabetes. What’s being missed and what this course was built to teach is the third use case: microdosing GLP-1 RAs as a precision metabolic and longevity tool for patients who don’t fit the standard mold.
Perimenopause. Postmenopause. Andropause. PCOS. Early insulin resistance. Sleep apnea. CVD prevention. Patients who’ve tried standard-dose GLP-1s and quit because the side effects were intolerable. These patients are filling cash-based wellness practices right now — and they are actively searching for providers who understand there’s more to GLP-1 therapy than maximum titration.
This course gives you the full clinical and business framework to serve them. You’ll learn the pharmacologic rationale for microdosing, how to map GLP-1 therapy to the eight drivers of insulin resistance, how to stack it with HRT and lifestyle interventions for synergistic outcomes, and how to run a profitable monthly membership model around it. Three hours. Six modules. One complete practice model — built by a women’s health NP who does this every day.
$499 - 4 CE Hrs (3 Rx) - Self-Paced Online - Lifetime Access
The Highest-Demand Service Line in Cash-Based Practice. Are You Ready to Offer It Correctly?
GLP-1 receptor agonists have become the most recognized drug class in the country. According to KFF (2024), 80% of US adults have heard of them — and 12% have already used one. But 54% report difficulty affording them, and a significant portion who start standard-dose protocols stop within months because the side effects are too severe. This is not a demand problem. It’s a delivery problem.
The standard titration protocol — start at 0.25 mg, escalate to 2.4 mg — maximizes weight loss on paper. It also maximizes GI side effects, dropout rates, and lean mass loss. Higher doses mean more nausea, more constipation, and more patients who lose muscle instead of fat because no one taught them about protein, resistance training, or body composition monitoring.
Microdosing changes the equation. By staying below the smallest available commercial dose and extending dosing intervals to 10, 14, 21, or 28 days, providers can deliver meaningful metabolic benefit with dramatically better tolerability and adherence. Seier et al. (2025) showed average weight loss of 16.7% at just 1.02 mg/week average semaglutide dose, with 98% achieving at least 5% body weight loss. Wu et al. (2025) showed every-14-day dosing retains approximately 72% of weekly-dosing weight loss — while cutting dose frequency in half.
This course is not a general GLP-1 overview. It’s a specialized curriculum for NPs who want to use these agents at the intersection of metabolic medicine, hormone optimization, and longevity care — and build a profitable, scalable practice around doing it well.
This course is built for Nurse Practitioners and licensed healthcare providers ready to expand their practice with GLP-1 microdosing protocols. Ideal for those seeking current, actionable clinical strategies for metabolic health and private practice growth.
Course Overview
Six modules. Three hours. A complete clinical and business framework for GLP-1 microdosing in private practice.
This course opens with a foundational reframe: GLP-1 receptor agonists are not just diabetes drugs. They are multi-system agents targeting seven of the eight known contributors to insulin resistance simultaneously. Module 1 establishes this mechanistic case, defines the three levels of GLP-1 RA use, and introduces microdosing as a longevity lever: a targeted intervention that preserves muscle, reduces inflammation, and supports long-term metabolic health at doses well below standard therapeutic thresholds.
Module 2 maps the metabolic terrain — hormonal status (HRT, thyroid), chronic inflammation, gut health, and micronutrient deficiencies — and covers the emerging GLP-1 and HRT synergy data, including Castaneda (2025) ENDO data showing MHT users on tirzepatide lost significantly more weight at 15 months. Module 3 covers movement, nutrition, and behavior science: protein targets (1.6–2.2 g/kg/day), resistance training, time-restricted eating, circadian alignment, and behavioral tools.
Module 4 is the prescribing core: microdosing timeline, starting doses and titration strategy, body composition monitoring with InBody, key metabolic labs (FSI, HOMA-IR, ApoB, hs-CRP), when to increase, hold, or taper, and side effect management. Module 5 builds the practice: monthly membership model with real cost/pricing data, compounding pharmacy guidance, documentation for off-label use, and marketing strategies. Module 6 covers special populations, sex-specific protocols, CVD prevention, and the future of GLP-1 research.
Meet Your Instructor
Ann Konkoly, MBA, MSN, APRN-CNP, WHNP-BC, MSCP
Ann is a Women’s Health NP, Certified Nurse-Midwife, Certified Life & Business Coach, and DNP candidate. She is the founder of Kultivate Women’s Health and Authentic Koaching. Ann has won multiple awards, including ACNM “Young Whippersnapper,” UH APRN Clinical Excellence, and ACNM Outstanding Preceptor. She is also a former faculty member at UH Cleveland Medical Center, Case Western Reserve University, Vanderbilt University School of Nursing, and OSU. Her specialties include midlife care, HRT/TRT, medical weight management, and private practice mentorship.
Turn GLP-1 microdosing into your next revenue stream without sacrificing patient safety or outcomes...
Learn the proven protocol that helps patients lose weight, preserve muscle, and improve metabolic health while you grow your practice...
Discover how to integrate GLP-1 microdosing into your clinic with confidence, compliance, and a membership model patients love...
GLP-1 RA Microdosing Curriculum
Course Expires: 10/31/2028
- Course Disclosure
- Downloadable Presentation Slides
- Course Pre-Test
- Section 1 - Course intro: uses of GLP-1s, the longevity lever, and the HRT parallel (35:51)
- Section 1.1 - What is a GLP-1 RA? Considerations, properties, and an introduction to microdosing (34:58)
- Section 2 - The metabolic terrain: HRT and tirzepatide in women and men, and lab testing (52:53)
- Section 3 - Movement, nutrition, and behavior: training regime protocols (20:06)
- Section 3.1 - Time-restricted eating, nutritional education, and mindset tools for weight loss (31:26)
- Section 4 - Microdosing protocols and tracking progress: starting doses, titration strategies, and side effect mitigation (8:03)
- Section 5 - Practice model integration: memberships and marketing (21:38)
- Section 6 - Special populations, risks, and future vision: combining with microdosing and case study (18:36)
- Course Post-Test
- Downloadable Audio Lectures
- Additional Resources: Consent, Lab Orders, Policies, and More!
- Course Evaluation
A Message from the Author:
Frequently Asked Questions
Who is this course designed for?
This course is for nurse practitioners and advanced practice providers who want to use GLP-1 receptor agonists at sub-therapeutic doses as a precision metabolic and longevity tool — either in an existing cash-based wellness practice or as a new service line. Appropriate for providers at any level of GLP-1 prescribing experience.
What exactly is microdosing and how is it different from standard GLP-1 prescribing?
GLP-1 RA microdosing uses doses below the smallest available commercial threshold — typically starting at 0.125–0.25 mg semaglutide weekly — and often extends dosing intervals to every 10, 14, 21, or 28 days. The goal is to find the sweet spot: lowest dose producing meaningful metabolic benefit with minimal GI side effects and superior long-term adherence. Critically, cutting the dose in half does not cut results in half — Wu et al. (2025) shows 50% frequency dosing retains approximately 72% of weekly dosing weight loss outcomes.
Is microdosing FDA-approved?
No. Microdosing GLP-1 RAs is an off-label application of agents FDA-approved for Type 2 diabetes and/or obesity. The course covers informed consent documentation, clinical rationale for off-label use, compounding pharmacy options with current FDA compliance guidance, and the alternative approach of microdosing FDA-approved vials at lower doses.
Does the course cover the business side of building a microdosing service?
Yes — this is a full dual-track curriculum. Module 5 is dedicated entirely to practice integration: a monthly membership pricing model with a real 6-month cost pro forma, bundled service structure, membership terms and cancellation policies, documentation and consent templates, compounding pharmacy sourcing guidance, and both organic and digital marketing strategies.
How do GLP-1s interact with hormone replacement therapy?
Emerging data strongly suggests synergy. A Mayo Clinic retrospective (Hurtado et al., 2024) found postmenopausal women on semaglutide achieved greater weight loss when concurrently on hormone therapy. ENDO 2025 data (Castaneda) found menopausal women on tirzepatide + MHT lost 18.7% body weight versus 13.7% in non-MHT users by month 15. For men, La Vignera et al. (2025) showed tirzepatide improved endogenous testosterone, SHBG, LH, FSH, and erectile function beyond what TRT or lifestyle alone achieved.
How do I access the course?
Immediately after enrollment, you will receive full access to all course content through your EliteNP student portal. The course is completely self-paced, work through the six modules in order or revisit individual sections as needed. Lifetime access is included.
See what others have said…
Shannon A: "Very, very helpful whatever practice you are trying to set up. The courses have an underlying feel that they are truly on your side and trying to help you be successful! You will NOT regret using Elite NP for your practice/professional needs!"
Rose: "There is something for every NP! I have been taking classes offered by the Elite NP since 2021. The content is clear, effective, and supported. Justin gives you the information in a step-by-step method to get your new venture up and running. I have been dealing with ‘analysis paralysis’ for a while. I kept listening to his podcasts and reviewing classes until I finally felt ready to pull the trigger. Thank you Elite NP for the information, encouragement and support to help us advance!"
Jeffrey A: "I am currently practicing independently now because of the courses being offered through the Elite NP. Justin's site is my go-to site now. The customer service is great the information is great. I strongly recommend any active nurse practitioner who is looking to break out of the grind and become independent to look into these courses and his site. Every time I visit his site I have new ideas for my independent practice I'm becoming very confident in my ability to keep expanding as an independent nurse practitioner. Again I strongly recommend any nurse practitioner looking to seek Independence to just begin taking a course of interest. That's all it took for me was taking one course and everything has changed. I wish you all the best of luck. And Justin keep up the good work."
All Elite NP CEU applies to ANCC and AANP recertification and can be used with all Boards of Nursing.
The Elite Nurse Practitioner is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation
Interested in learning more? Check out the rest of The Elite Nurse Practitioner course line up!
Interested in bundling some courses? Visit our bundle checkout for big savings:
